Nuvectis Pharma Receives First Global Approval for Ciprocopan in China for PNH Treatment

Key Facts

In a move reflecting a significant milestone for the global biotech sector, Nuvectis Pharma announced that its drug ciprocopan (NXP100) received its first global marketing approval in China. The drug is a once-daily oral inhibitor designed to treat patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are treatment-naive. According to reports, this approval marks the company's successful entry into the Chinese pharmaceutical market with an innovative therapeutic alternative.

The regulatory approval was based on Phase 3 trial results where ciprocopan demonstrated superiority over Soliris, with 59.5% of patients reaching target hemoglobin levels. This clinical progress comes as Chinese economic data shows monetary policy stability, with the Prime Rate holding at 3% as of July 20, 2026, per market data. This achievement is a pivotal step for Nuvectis in developing therapies for complement-mediated diseases.

Operationally, markets are now watching the company's ability to expand the drug's distribution beyond China following this initial success. Looking at the economic calendar, there are no upcoming catalysts directly linked to the company, leaving the focus on the partnership details with Haisco for global commercialization.